deucravacitinib,apremilast
bms,amgen
['psoriasis', 'deucrava', 'deucra']
u.s. food and drug administration approves sotyktu (deucravacitinib), oral treatment for adults with moderate-to-severe plaque psoriasis #pharmanews #clinicalresearchnews #biotechnews #lifesciencesnews #medicalnews #healthcarenews #pharmiwebnews 
News from across the pharmaceutical and biotech industry from PharmiWeb https://t.co/ea1b58MZYg